Temporal and Spatial Heterogeneity of Host Response to SARS-CoV-2 Pulmonary Infection.

Autor: Desai N; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Neyaz A; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Szabolcs A; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Shih AR; Department of Pathology, Boston, MA 02114, USA., Chen JH; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.; Department of Pathology, Boston, MA 02114, USA., Thapar V; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Nieman LT; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Solovyov A; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Mehta A; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.; The Broad Institute, Cambridge, MA 02142, USA., Lieb DJ; The Broad Institute, Cambridge, MA 02142, USA., Kulkarni AS; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Jaicks C; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Pinto CJ; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Juric D; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Chebib I; Department of Pathology, Boston, MA 02114, USA., Colvin RB; Department of Pathology, Boston, MA 02114, USA., Kim AY; Department of Medicine, Boston, MA 02114, USA., Monroe R; Advanced Cell Diagnostics, a Bio-Techne Brand, Newark, CA 94560, USA., Warren SE; NanoString Inc., Seattle, WA 98109, USA., Danaher P; NanoString Inc., Seattle, WA 98109, USA., Reeves JW; NanoString Inc., Seattle, WA 98109, USA., Gong J; NanoString Inc., Seattle, WA 98109, USA., Rueckert EH; NanoString Inc., Seattle, WA 98109, USA., Greenbaum BD; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Hacohen N; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.; Department of Medicine, Boston, MA 02114, USA.; The Broad Institute, Cambridge, MA 02142, USA., Lagana SM; Columbia University Irving Medical Center, Department of Pathology and Cell Biology, New York, NY 10032, USA., Rivera MN; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.; Department of Pathology, Boston, MA 02114, USA.; The Broad Institute, Cambridge, MA 02142, USA., Sholl LM; Brigham and Woman's Hospital, Department of Pathology, Boston, MA 02115., Stone JR; Department of Pathology, Boston, MA 02114, USA., Ting DT; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.; Department of Medicine, Boston, MA 02114, USA., Deshpande V; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.; Department of Pathology, Boston, MA 02114, USA.
Jazyk: angličtina
Zdroj: MedRxiv : the preprint server for health sciences [medRxiv] 2020 Aug 02. Date of Electronic Publication: 2020 Aug 02.
DOI: 10.1101/2020.07.30.20165241
Abstrakt: The relationship of SARS-CoV-2 lung infection and severity of pulmonary disease is not fully understood. We analyzed autopsy specimens from 24 patients who succumbed to SARS-CoV-2 infection using a combination of different RNA and protein analytical platforms to characterize inter- and intra- patient heterogeneity of pulmonary virus infection. There was a spectrum of high and low virus cases that was associated with duration of disease and activation of interferon pathway genes. Using a digital spatial profiling platform, the virus corresponded to distinct spatial expression of interferon response genes and immune checkpoint genes demonstrating the intra-pulmonary heterogeneity of SARS-CoV-2 infection.
Databáze: MEDLINE